Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: an open-label extension study.

Chronic sodium selenate treatment is safe and well tolerated in patients with AD. Cognitive measures suggest a slowing of disease progression though this could not be confirmed as the study was not controlled. Further research into sodium selenate as a treatment for AD is warranted.